Yair Einhorn
@yaireinhorn
#Science & #Innovation. Special interest in #BioTech, #GeneEditing, #EpiGeneticEditing, #GeneTherapy 🧬 #CRISPR & #Ophthalmology. #Markets & #Stocks 📈
ID:1238780417324580867
14-03-2020 10:54:12
7,8K Tweets
7,3K Followers
44 Following
1/Intellia Therapeutics & $REGN announced an expanded collaboration to develop in vivo #CRISPR -based #GeneEditing therapies focused on neurological & muscular diseases which will combine $NTLA proprietary Nme2Cas9 platform & Regeneron viral vector delivery technologies. #BioTech $XBI
1/SparingVision has announced positive initial safety data from its Phase I/II PRODYGY clinical trial of SPVN06-a gene-agnostic #GeneTheapy aimed to stop/slow the disease progression of #RetinitisPigmentosa - one of the leading inherited causes of blindness. #BioTech $XBI $NTLA
My article on how to scale a cell therapy start-up #scalability #ipsc #crispr #geneediting #strategy #capitalmarkets #partnerships #CDMO #exit Cell&Gene BioInformant Endpoints News FierceBiotech STAT cellandgene.com/doc/a-point-bu…